Abstract
Purpose PIONEER-HF established the safety of the angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril-valsartan (S/V), in patients hospitalized with acute decompensated heart failure after achieving hemodynamic stability. We have previously shown that transitioning patients in ADHF with low cardiac output directly from intravenous (IV) vasoactive (i.e. vasodilators or inotropes) drugs to ARNI can be done safely with tolerance to one-month follow-up. Here we further characterize the acute hemodynamic impact of ARNI therapy after patients have been optimized on IV vasoactive therapy. Methods A single-center, retrospective analysis of all patients with HFrEF (EF Conclusions ICU patients can be successfully bridged from vasoactive IV therapy to oral ARNI with sustained improvement in cardiac index garnered from vasoactive agents. We also observed improvement in PAPI along with maintenance of LV/RV unloading with ARNI. These encouraging findings merit prospective validation of ARNI compared to more commonly used oral vasodilators in ICU care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
